From bench to bedside: the evolution and future of prostate-specific antigen testing.

Area of Science:

• Urology
• Oncology
• Biochemistry

Background:

• Prostate cancer is a leading cancer in males in the U.S.
• Prostate-Specific Antigen (PSA) is a key biomarker for prostate cancer diagnosis and management.
• PSA has been clinically utilized for screening since FDA approval in 1994.

Purpose of the Study:

• To review the historical development and properties of PSA.
• To analyze the clinical applications of PSA in prostate cancer detection, staging, and monitoring.
• To discuss current limitations and future innovations for enhancing PSA's diagnostic accuracy.

Main Methods:

• Literature review of historical development, biochemical properties, and clinical applications of PSA.
• Analysis of advantages (early detection, mortality reduction) and limitations (false positives, overdiagnosis) of PSA testing.
• Exploration of recent innovations including PSA derivatives, imaging, urinary biomarkers, and risk calculators.

Main Results:

• PSA testing offers benefits in early prostate cancer detection and reducing mortality.
• Limitations of PSA testing include false positives, overdiagnosis, and overtreatment risks.
• Emerging tools aim to improve diagnostic accuracy and personalize screening strategies.

Conclusions:

• PSA remains a valuable but imperfect biomarker in prostate cancer care.
• Ongoing research focuses on enhancing PSA specificity and integrating it into personalized screening.
• Improved understanding and application of PSA can aid clinicians in effective prostate cancer management.